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Myxedema crisis is a severe life threatening form of decompensated hypothyroidism which is associated with a high mortality
rate. Infections and discontinuation of thyroid supplements are the major precipitating factors while hypothermia may not play a
major role in tropical countries. Low intracellular T3 leads to cardiogenic shock, respiratory depression, hypothermia and coma.
Patients are identiﬁed on the basis of a low index of suspicion with a careful history and examination focused on features of
hypothyroidism and precipitating factors. Arrythmias and coagulation disorders are increasingly being identiﬁed in myxedema
crisis. Thyroid replacement should be initiated as early as possible with careful attention to hypotension, ﬂuid replacement and
steroid replacement in an intensive care facility. Studies have shown that replacement of thyroid hormone through ryles tube
with a loading dose and maintenance therapy is as eﬃcacious as intravenous therapy. In many countries T3 is not available
and oral therapy with T4 can be used eﬀectively without major signiﬁcant diﬀerence in outcomes. Hypotension, bradycardia at
presentation, need for mechanical ventilation, hypothermia unresponsive to treatment, sepsis, intake of sedative drugs, lower
GCS and high APACHE II scores and Sequential Organ Failure Assessment (SOFA) scores more than 6 are signiﬁcant predictors
of mortality in myxedema crisis. Early intervention in hypothyroid patients developing sepsis and other precipitating factors and
ensuring continued intake of thyroid supplements may prevent mortality and morbidity associated with myxedema crisis.
“No decision is easy, Sue.
It only looks that way when you’re young.
When you’re older, everything is complicated.
T h e r ei sn ob l a c ka n dw h i t e ,o n l yg r e y . ”
—Dr. George A. Harris in the movie Coma 1978.
1.Introduction
Myxedema coma is a severe and life-threatening form of de-
compensated hypothyroidism with an underlying precipitat-
ing factor. The mortality rates may be as high as 25–60%
evenwithbestpossibletreatment[1–5].Thetermmyxedema
coma is a misnomer, and myxedema crisis may be an apt
termasquiteafewpatientsareobtunded,ratherthanfrankly
comatose. As the disease is rare and unrecognized, we only
have a few isolated case reports and case series, and there is a
dearth of randomized controlled trials in the ﬁeld of myx-
edema crisis. At present there are over 300 cases reported
in literature [6–8]. In this paper we discuss the standard
clinical presentation, treatment, predictors of mortality, and
controversies that overshadow the current concepts in the
management of myxedema crisis.
The need of the hour is to ﬁnd answers to some burning
questions which may change the way we manage myxedema
crisis. Some of these questions include the following:
(a) whatarethepreventableprecipitatingfactorsinmyx-
edema crisis?
(b) are there any geographical variations involved in the
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(c) how can we identify myxedema crisis at an early
stage?
(d) are there ways by which we can identify patients at
risk of dying?
(e) whatisthestatusofintravenousandoralreplacement
therapy with T4 and T3?
At present, we need more well-designed studies to address
some of these questions.
1.1. Epidemiology. Case series and case reports from western
world tell us that the incidence of myxedema crisis is about
0.22 million per year, but there is a scarcity for such epidemi-
ological data from countries that lie around the equator [9].
Epidemiology of myxedema crisis follows the same pattern
as in hypothyroidism and is more common in women and
elderly.
1.2. Precipitating Events. Literature reveals that most cases
present in winter, and hypothermia is a common manifesta-
tion. Low ambient temperature may alter thermoregulatory
mechanisms and hence will lower the threshold for enceph-
alopathy [1]. However, in our own experience, the presenta-
tion may be only slightly more in winter months, and the
incidence of severe hypothermia may be lower in tropical
countries such as ours as temperatures below 10 degree
Celsius are rare, and ambient temperature may inﬂuence the
degreeofhypothermia(unpublisheddata).Inourexperience
quite a few patients with myxedema crisis have temperatures
2-3◦Fbelownormalalthoughwealsoseepatientswithsevere
hypothermia.
Infections and septicemia are the leading precipitating
factors [2, 3]. Typical infections include pneumonia, urinary
tract infections, and cellulitis. Cerebrovascular accidents,
congestive cardiac failure, road traﬃc accidents, gastroin-
testinal bleeding, and various sedative drugs may play a role
in precipitating myxedema crisis. Diuretics may mask some
of the myxedematous features, and they may also aggravate
the hyponatremia associated with myxedema crisis.
Recently, Chu and Seltzer reported a case of myxedema
crisisprecipitatedbyconsumptionofrawbokchoy[10].Bok
choyorChinesewhitecabbagecontainsglucosinolates.Some
of the breakdown products of glucosinolates, such as thio-
cyanates, nitriles, and oxazolidines, have been implicated for
their inhibitory eﬀects on the thyroid as they may inhibit the
uptake of iodine. When eaten raw, brassica vegetables release
the enzyme myrosinase, which accelerates the hydrolysis of
glucosinolates. Cooking deactivates myrosinase.
A commonly ignored background factor in myxedema
crisis is the discontinuation of thyroid supplements in criti-
cally ill patients. This is possibly due to the fact that attention
may be focused on presenting features and precipitating
factors, and associated hypothyroidism is generally ignored
(Box 1).
2. Pathogenesis of Myxedema Crisis
Low intracellular T3 secondary to hypothyroidism is the
basic underlying pathology in myxedema crisis which leads
Hypothermia
Infections and septicaemia
Cerebrovascular accidents
Congestive heart failure
Gastrointestinal bleeding
Consumption of raw bok choy
Trauma and fractures
Drugs—anaesthetics, sedatives, tranquilizers, narcotics,
amiodarone, and lithium
Withdrawal of thyroid supplements
Box 1: Precipitating factors of myxedema crisis.
tohypothermiaandsuppressionofcardiacactivity.Thebody
tries to compensate by neurovascular adaptations including
chronicperipheralvasoconstriction,milddiastolichyperten-
sion, and diminished blood volume.
Decreased central nervous system sensitivity to hypoxia
and hypercapnia leads to respiratory failure [11, 12]. Other
factors contributing to respiratory failure include respiratory
muscle dysfunction, obesity, pleural eﬀusions, macroglossia,
reduced lung volume, myxedema of the nasopharynx and
larynx (reduces the eﬀective airway opening), pneumonia,
and aspiration [12–14].
Altered vascular permeability leads to eﬀusions and an-
asarca. Water retention and hyponatremia occurs secondary
to reduced glomerular ﬁltration rate, decreased delivery to
the distal nephron [15], and excess vasopressin [16, 17]
(Figure 1).
Low intracellular T3 leads to depressed cardiac functions
with decreased inotropism and chronotropism with vaso-
constriction. The hypothyroid heart tries to perform more
work at a given amount of oxygen by better coupling of ATP
to contractile events. A precipitating factor pushes this pre-
carious balance over the brink [18]. In the decompensated
state, low cardiac output and hypotension will result in car-
diogenic shock which may not be responsive to vasopressors
without thyroid hormone replacement [11].
Decreased gluconeogenesis, precipitating factors like
sepsisandconcomitantadrenalinsuﬃciency,maycontribute
tohypoglycemia.Inadditiontothegeneralizeddepressionof
cerebral function, hyponatremia, hypoglycemia, hypoxemia,
and reduced cerebral blood ﬂow can precipitate focal or
generalized seizures and worsen the level of consciousness.
3.ClinicalFeatures
Alowindexofsuspicionandasearchforprecipitatingfactors
should be initial step in dealing with myxedema crisis at an
earlier stage. History should focus on the presence of thyroid
dysfunction, dose of thyroid hormone, discontinuation of
thyroid supplements, thyroid surgery, radioactive iodine
ablation,andadetailedrecordofdrugintakeforbackground
diseases. Central hypothyroidism may constitute about 5%
of all the cases of myxedema crisis [1]. Physical examination
should focus on features of severe hypothyroidism like
dry skin, sparse hair, a hoarse voice, hypothermia, delayed
tendon reﬂexes, macroglossia, nonpitting edema, goiter, andJournal of Thyroid Research 3
Fluid retention
Hyponatremia
Hypothyroidism and precipitating factor
Low serum T4 and intracellular T3
Decreased inotropism and chronotropism Hypothermia Stupor
Cardiogenic shock Respiratory failure Worsening mental status
COMA
Figure 1: Pathogenesis of myxedema crisis.
surgical scar of thyroidectomy in addition to recording vital
functionsandlevelofconsciousness.Presenceoforbitopathy
may be a subtle clue to underlying Graves’s disease which
may have been treated with radioiodine or surgery.
Dutta et al. studied 23 patients with myxedema crisis and
found that 39% of them had hypothyroidism detected only
at the time of crisis. It should be noted that 17% of these
patients had central hypothyroidism which was higher than
the previous reported percentage of 5%. Sepsis was the most
common precipitating factor, and a signiﬁcant proportion of
patients (61%) had defaulted on thyroid supplements [4].
Reinhardt and Mann reported hypoxemia in 80%, hypercap-
nia in 54%, and hypothermia with a temperature less than
94◦F in 88% of all the patients with myxedema crisis [5].
Sinus bradycardia, low voltage complexes, bundle branch
blocks, complete heart blocks, and nonspeciﬁc ST-T changes
in electrocardiogram have been recorded in myxedema crisis
[4,19].Schencketal.reportedapatientwithseverehypothy-
roidism who presented with presyncope, prolongation of
the QT interval, and polymorphic ventricular tachycardia
(torsades de pointes) which reversed with thyroid hormone
supplementation [20]. Prolongation of QT interval and in-
creased QT dispersion, a marker of electrical instability [21,
22], have been documented in severe hypothyroidism [23].
These anomalies have been shown to be reversible in sub-
clinical hypothyroidism [24]. Increased myocardial ﬁbrosis
in severe hypothyroidism may lead to a resistance in im-
provement of QT dispersion with thyroid hormone supple-
mentation [24]. The study of heart rate variability param-
eters also indicate that hypothyroidism leads to a sympa-
thovagal imbalanced state, characterized by both decreased
cardiovascular sympathetic and vagal modulation [23]. The
occurrence of malignant arrhythmias needs to be recognized
in long-standing hypothyroidism and myxedema crisis [19,
23, 25]( Table 1).
An important practical aspect may be the identiﬁcation
of pericardial eﬀusion and myocardial infarction in a setting
of myxedema crisis. Low-voltage complexes and nonspeciﬁc
ST-T changes can be seen in pericardial eﬀusion. Cardiac
enzymes should be done with a suspicion of myocardial
infarction.
Patients with myxedema crisis may have normocytic
normochromicanemiawhichmaybesecondarytodecreased
oxygen requirement and erythropoietin [26]. Macrocytic
blood picture may be seen with associated low folate absorp-
tion and pernicious anemia [27–29]. Severely hypothyroid
patients may have bleeding manifestations, and investiga-
tions reveal prolonged bleeding time and clotting time, de-
creasedplateletadhesiveness,elevatedAPTT,andlowornor-
mal factor VIII activity. Acquired von Willebrand’s disease
is also reported in hypothyroidism with decreased von
Willebrand factor antigen and activity [30]. Acquired von
Willebrand’s disease is very likely to be type 1 in all cases
because of a normal ratio of von Willebrand’s factor antigen
to ristocetin cofactor r [31]. The underlying defect could
possibly be a decreased synthesis of von Willebrand factor
in the absence of adequate levels of thyroxine [32], and
thyroxine replacement corrects these abnormalities [31, 33].
Erfurth and group have demonstrated that desmopressin
immediately reduced bleeding time, enhanced platelet adhe-
siveness, and signiﬁcantly increased plasma concentrations
of factor VIII and von Willebrand’s factor and hence may
be valuable for the acute treatment of bleeding or as cover
for surgery in a setting of myxedema crisis or severe hypo-
thyroidism [33].
Othercommonbiochemicalanomaliesinmyxedemacri-
sis include increased levels of creatine phosphokinase, lactate
dehydrogenase, aspartate transaminase, and hypercholes-
terolemia (elevated LDL) [34].
4.Diagnosis
Patients with altered sensorium, hypothermia, or absence
of fever despite infectious disease, clinical and biochemical4 Journal of Thyroid Research
Table 1: Clinical and laboratory features of myxedema crisis.
Cardiovascular Neuropsychiatric
Bradycardia and hypotension Confusion and obtundation
Cardiomegaly Lethargy
Low cardiac output Coma
Pericardial eﬀusion Seizures
Cardiogenic shock Poor cognitive function
Bundle branch blocks and arrhythmias Depression and psychosis
Nonspeciﬁc ECG ﬁndings
Respiratory Renal and water metabolism
Hypoxia Fluid retention
Hypercarbia Anasarca
Myxedema of larynx Hyponatremia
Pleural eﬀusion Bladder atony
Pneumonia (precipitating factor) Urine sodium normal or increased
Urine osmolality > serum osmolality
Gastrointestinal Metabolic
Anorexia and nausea Hypothermia
Abdominal pain Hypoglycemia
Constipation
Paralytic ileus
Toxic megacolon
Gastric atony
Neurogenic oropharyngeal dysphagia
features of hypothyroidism, those who had a history of hy-
pothyroidism and are currently not on treatment, in the set-
ting of a precipitating factor, should be identiﬁed with a high
indexofsuspicion.Thetreatingphysicianshouldnothesitate
in starting replacement therapy while waiting for serum TSH
and serum T4. An active search for precipitating causes
should be initiated, and appropriate investigations should be
ordered based on patient’s clinical presentation. White blood
cell counts, urine routine and microscopy, blood and urine
culture, serum electrolytes, serum creatinine, chest X-ray,
and electrocardiogram should be obtained.
Clinician may face multiple diagnostic dilemmas. First,
in central hypothyroidism, TSH may be unusually low. The
deciding factor here will be associated pituitary hormone
deﬁciencies as isolated central hypothyroidism is rare. In the
second situation, the systemic illness will produce a picture
akin to sick euthyroid syndrome, and the elevation in TSH
may not be as high as expected, but the T3 levels here may
be unusually low as there is decreased conversion of T4 to
T3 [34, 35] with elevated reverse T3. Finally, the presenting
featuresofmyxedemacrisismayalsobecommonlyseenwith
associated sepsis, stroke, and dyselectrolytemia, and hence
the diagnosis is often delayed.
It may be appropriate at this juncture to discuss the
rare entity of Hashimoto’s encephalopathy which is a rare
complication of Hashimoto’s thyroiditis [36]. The condition
may present as a subacute or acute encephalopathy with
seizures, stroke-like episodes, myoclonus, and tremor [37].
Patients will have elevated thyroid-speciﬁc autoantibodies
(Anti-TPO), elevated cerebrospinal ﬂuid protein without
pleocytosis, and abnormal electroencephalogram [38]. The
keypointstoconsiderhereisthatmostpatientsareeuthyroid
and the condition is steroid responsive [39].
5. Treatment of Myxedema Crisis
Treatment of myxedema crisis should be prompt and multi-
dimensional with attention to the following principles:
(a) intensive care treatment with ventilator support, cen-
tral venous pressure monitoring, and pulmonary
capillary wedge pressure if feasible in patients with
cardiac disease,
(b) appropriate ﬂuid management and correction of hy-
potension and dyselectrolytemia,
(c) aggressive management of precipitating factors and
steroid supplementation if required,
(d) thyroid hormone replacement.
6. General Measuresin Management
Management of airway and airway protection from aspira-
tion in case of patients with poor consciousness level should
be the utmost priority. Endotracheal intubation or tra-
cheostomy with mechanical ventilation may be performed.
Arterial blood gas should be monitored frequently to en-
sure adequate oxygenation and correction of hypercarbia.Journal of Thyroid Research 5
Sedatives and other drugs may exacerbate the respiratory
depression and may delay the weaning of ventilator support
[40].
Fluid management evokes a Damocles sword type situ-
ation in myxedema crisis where the choice is between ﬂuid
supplementation for hypotension and ﬂuid restriction for
hyponatremia. A pragmatic approach in mild hyponatremia
will be to advice ﬂuid restriction with replacement to cover
the daily losses taking care to supplement glucose, sodium,
and potassium [41]. In a situation of severe hyponatremia,
it may be prudent to administer 3% sodium chloride along
with furosemide, so that serum sodium may be elevated by
3-4meq/L to tide over the immediate crisis [42]. A rapid
correction of chronic hyponatremia might put patients at
riskforcentralpontine myelinolysis[43,44].Treatmentwith
furosemide will prevent ﬂuid overloading associated with
hypertonic saline. In experimental hypothyroidism, the im-
paired response to an acute water load was shown to be
reversed by a Vasopressin receptor antagonist (V2R antag-
onist) [17]. Future research with V2R antagonists in treating
hyponatremia associated with myxedema crisis may prove to
be interesting.
Hypothermia may be managed by external warming, but
the accompanying vasodilatation may precipitate hypoten-
sion.Hypotensionrequirescarefulinfusionofdextrosesaline
solutions and vasopressors if required. A search for other
causes of hypotension like sepsis, myocardial infarction, per-
icardialeﬀusion,andoccultbleedingshouldbeinitiated.Ina
setting of concomitant adrenal insuﬃciency, hydrocortisone
supplementation is also required for correction of hypoten-
sion.
Hypocortisolemia may be due to primary or secondary
adrenal insuﬃciency. The clinical features of myxedema cri-
sis and cortisol deﬁciency may overlap. Hyperpigmentation,
hyperkalemia,hypercalcemia,andprevioushistoryofonand
oﬀ steroid use must be sought. Thyroid hormone replace-
ment may increase cortisol clearance and may aggravate cor-
tisol deﬁciency. If the facilities for HPA axis evaluation are
not available on an emergency basis, steroid therapy may
start and a formal evaluation of axis is done at a later date
when patient is stable. Intravenous hydrocortisone is pre-
ferred at a rate of 50mg every 6 hours.
It cannot be overemphasized that the precipitating fac-
tors require urgent attention with antibiotics in case of infec-
tion, hemodialysis for associated renal failure, and compre-
hensive care of multiorgan dysfunction.
7. Thyroid Hormone Therapy
Thyroid hormone therapy is the backbone of treatment of
patientswithmyxedemacrisis.Themainconsiderationswith
thyroid hormone replacement are the absorption and distri-
bution of administered hormone preparation, the onset of
action and eﬃcacy of the preparation, and ﬁnally the safety.
At present, oral and intravenous T4 and T3 are used. The
major considerations are the dose, route of administration,
and frequency of administration.
T4 therapy provides a steady, smooth, and slow onset of
action with relatively few adverse events. In many countries,
T3 may not be available, but T4 is easily available at hand. T4
therapy avoids major peaks and troughs in body, and values
of serum T4 may be easy to interpret [1]. However, T3 is
the active hormone in the body, and in a setting of severe
illness there may be a decreased conversion of T4 to T3 [34].
ParenteralT4maybe usedat adose of300–500µgasbol ust o
saturatethebodypool.Theusualprotocolthenistocontinue
T4atadoseof50–100µgdaily.Thereareenoughstudiesthat
h a v eu s e dal a r g eb o l u sd o s eo fT 4a sd e s c r i b e de a r l i e r ,a n d
they demonstrate good results [45, 46]. T4 concentrations
rise acutely to levels above normal and slowly gets converted
to T3 [46].
Oral administration of T4 through Ryles tube has proved
to be equally eﬀectivewith a drawbackthat gastricatony may
prevent absorption and put the patient at risk for aspiration.
Dutta and colleagues compared 500µg of oral loading dose
of T4 with 150µg of maintenance dose orally and 200µgo f
T4 intravenously followed by 100µg T4 intravenously until
they regained their vital functions and were able to take oral
medications in patients with myxedema crisis and did not
ﬁnd any diﬀerence in outcome among the patients [4].
AdvantagesofusingT3includearapidonsetofaction,an
earlier beneﬁcial eﬀect on neuropsychiatric symptoms, and
signiﬁcant clinical improvement within 24 hours. T3 may
be given at a dose of 10 to 20µg, followed by 10µge v e r y
4 hours for the ﬁrst 24 hours and then 10µge v e r y6h o u r s
for 1 or 2 days till the patient is alert enough to continue
therapy through oral route. Measurable increases in body
temperature and oxygen consumption occur within 2 to 3
hours after intravenous administration of T3 but may take
8 to 14 hours or longer after intravenous administration of
T4 [1, 47]. However, poor availability of T3, ﬂuctuations
in serum levels of T3, and adverse cardiac eﬀects may limit
the use of T3. Yamamoto et al. reported that doses of LT4
more than 500µg per day and LT3 more than 75µg/day were
associated with increased mortality [3].
Combined therapy of T4 and T3 may also prove to be
useful. T4 may be initiated at a dose of 4µg/kg of lean body
weight,followedby100µg24hourslaterandthen50µgdaily
intravenously or orally. T3 may also be started simultane-
ously with T4 at a dose of 10µg iv, and the same dose is given
every 8 to 12 hours until the patient can take maintenance
oral doses of T4 [1].
8. FactorsPredictingthe Mortalityin
Myxedema Crisis
Dutta and colleagues looked at the predictors of outcome in
myxedema crisis and found that hypotension, bradycardia at
presentation, need for mechanical ventilation, hypothermia
unresponsive to treatment, sepsis, intake of sedative drugs,
lower GCS, and high APACHE II scores were signiﬁcant
predictors of mortality. Sequential organ failure assessment
(SOFA) score was more eﬀective than other predictive mod-
els. Baseline and day 3 SOFA scores of more than 6 were
highly predictive of poor outcome. They also demonstrated6 Journal of Thyroid Research
that treatment defaulters presented early to the hospital and
had more severe manifestations than de novo patients [4].
Rodr´ ıguezandcolleaguesshowedthatthosepatientswith
coma at the time of presentation, low Glasgow coma scale
scores, and higher APACHE II scores had considerably poor
outcome [2]. Studies have also shown that higher doses of
T3 are associated with increased mortality, and lower doses
of T3 and T4 may be associated with favorable prognosis
[3, 47, 48]. Other factors associated with mortality include
advanced age and cardiovascular disease [1, 3].
9. Summary
Myxedema crisis is a life-threatening extreme form of hypo-
thyroidism with a high mortality rate if left untreated. Myx-
edema crisis is commonly seen in older patients, especially
women, and is associated with signs of hypothyroidism, hy-
pothermia, hyponatremia, hypercarbia, and hypoxemia.
There may be a signiﬁcant delay in diagnosis which may ad-
versely aﬀect the prognosis. Patients should be provided with
intensive care facilities with prompt attention to ventilation,
hypotension, hypothermia, steroid replacement, and thyroid
hormone supplementation. SOFA scoring system may help
us to identify patients at risk of mortality at an earlier stage.
Early medical attention in hypothyroid patients developing
serious illness especially sepsis and ensuring continuation of
thyroid supplements may prevent signiﬁcant morbidity and
mortality.
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